Expand your market reach with Tris’ innovative technologies
Open up new market segments by offering sustained release products in alternative dosage forms for patients having difficulty swallowing pills. Our innovative OralXR+ technology offers sustained release in a variety of dosage forms such as liquid, chewable tablets, strips and ODT.
Protect your products from intentional and unintentional abuse
Nobuse™ is an abuse resistant proprietary technology applicable to all controlled substances and opiates for all oral dosage forms in immediate and sustained release versions.
News & Events |
Tris Pharma Announces Management Additions, Promotion Read More
Vernalis and Tris Pharma announce collaboration to develop and commercialize novel products for the US prescription cough/cold market (February, 2012) Read More
Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive (January, 2012) Read More
Tris Pharma Announces US Patent Grant Covering Platform Technology (January, 2012) Read More
Tris Pharma Expands Leadership Team, Adds Senior Managers in Quality and Finance (August, 2011) Read More
Extend your power to innovate
As a pioneer in the development of sustained release oral dosage forms, we dream big, never give up and relish in solving the unsolvable... Read More
